Drug Profile
Research programme: oncolytic viruses - Memorial Sloan-Kettering Cancer Center/Virttu Biologics
Latest Information Update: 24 Mar 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center; Virttu Biologics
- Developer Virttu Biologics
- Class Antisense elements; Gene therapies; Oncolytic viruses
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Mar 2023 Discontinued - Preclinical for Cancer in United Kingdom (Parenteral)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 28 Sep 2016 Preclinical development is ongoing in United Kingdom (Virttu Biologics pipeline, September 2016)